Heska Corporation Announces Q4 And Annual 2005 Results
LOVELAND, Colo., March 27 /PRNewswire-FirstCall/ -- Heska Corporation today reported financial results for its fourth quarter and year ended December 31, 2005.
Heska Corporation ("Heska" or the "Company") highlights for 2005 were: - Record revenue of $69.4 million - Decreased Operating Expenses by $4 million compared to 2004 - Improved Product Gross Margin by over 1 Percentage Point compared to 2004 - 200th U.S. Patent Issued - Announced Supply Agreement for Microalbuminuria Testing with Antech Diagnostics - Completed Corporate Headquarters Relocation to Centerra in Loveland, Colorado - Amended and Extended Credit Agreement with Wells Fargo to June 2009 - First Profitable Third Quarter - Improved Fourth Quarter Pre-tax Income by $1.5 million compared to 2004 - Net Income over $280 thousand - over a $5 million Improvement from 2004, including a $185 thousand non-recurring income tax benefit
"2005 was the best year in Heska history. We grew revenue to a record level and increased our product gross margin at the same time we decreased our operating expenses to their lowest level since we have been a public company -- and we accomplished this while introducing an exciting new product and moving into new corporate headquarters. All of our employees worked very hard in 2005 and I congratulate them on meeting our goal of annual profitability. This is an extremely important milestone for our company," said Robert Grieve, Heska's Chairman and CEO. "I am excited to lead our team into 2006 and am convinced we are poised for even greater success."
Segment Product Revenue
Total product revenue for the fourth quarter of 2005 was $15.6 million, down 5% from $16.3 million in the fourth quarter of 2004. For the year ended December 31, 2005, total product revenue was $67.5 million, up 3% from $65.7 million in 2004. Heska Corporation's business is comprised of two reportable segments -- Core Companion Animal Health and Other Vaccines, Pharmaceuticals and Products. Product revenue from these segments is as follows:
Core Companion Animal Health
This segment includes revenue from the company's diagnostic and monitoring instruments and supplies as well as single use, point-of-care tests, vaccines and pharmaceuticals, primarily for canine and feline use. In the fourth quarter of 2005, this segment generated product revenue of $13.0 million, up 2% as compared to $12.8 million in the fourth quarter of 2004. For the year ended December 31, 2005, this segment generated product revenue of $54.7 million, up 4% from $52.7 million in 2004.
Other Vaccines, Pharmaceuticals and Products
This segment includes revenue from private label vaccine and pharmaceutical production, primarily for cattle but also for other animals including small mammals, horses and fish. In the fourth quarter of 2005, this segment generated product revenue of $2.5 million, down 29% as compared to $3.5 million in the fourth quarter of 2004. For the year ended December 31, 2005, this segment generated product revenue of $12.8 million, down 1% from $13.0 million in 2004.
Investor Conference Call
Management will conduct a conference call on Monday, March 27, 2006 at 9:00 a.m. MST (11:00 a.m. EST) to discuss the fourth quarter and year end 2005 financial results. To participate, dial (800) 240-5318 (domestic) or (303) 262-2143 (international); the conference call access number is 11056588. The conference call will also be broadcast live over the Internet at http://www.heska.com. To listen, simply log on to the web at this address at least ten minutes prior to the start of the call to register, download and install any necessary audio software. Telephone replays of the conference call will be available for playback until April 10, 2006. The telephone replay may be accessed by dialing (800) 405-2236 (domestic) or (303) 590-3000 (international). The webcast replay may be accessed from Heska's home page at www.heska.com until April 10, 2006.
Heska Corporation sells advanced veterinary diagnostic and other specialty veterinary products. Heska's state-of-the-art offerings to its customers include diagnostic and monitoring instruments and supplies as well as single use, point-of-care tests, vaccines and pharmaceuticals. The company's core focus is on the canine and feline markets where it strives to provide high value products for unmet needs in veterinary medicine. For further information on Heska and its products, visit the company's website at www.heska.com.
This announcement contains forward-looking statements regarding Heska's future financial and operating results. These statements are based on current expectations and are subject to a number of risks and uncertainties. Investors should note that Heska does not expect to be profitable every quarter and Heska's current expectation is that the first quarter of 2006 will likely result in a net loss. In addition, factors that could affect the business and financial results of Heska generally include the following: uncertainties regarding Heska's ability to achieve sustained and/or material profitability; uncertainties regarding the accuracy of any current or future financial guidance; risks regarding Heska's ability to successfully market, sell and distribute its products; uncertainties regarding Heska's reliance on third parties who Heska has granted substantial marketing rights to certain of Heska's existing products; uncertainties regarding Heska's ability to raise additional capital or borrow additional cash to fund future operations as needed; competition; risks regarding the commercialization and market acceptance of products Heska may introduce in the future; risks regarding Heska's ability to continue to comply with all requirements of the credit and security agreement with Wells Fargo Business Credit, Inc.; uncertainties regarding the outcome of relationships and collaborations with third parties from which Heska is hoping to generate new product opportunities; risks regarding Heska's reliance on key personnel; uncertainties regarding the impact of revenue fluctuations or shortfalls versus our expectations on Heska's cash flow and liquidity as many of Heska's expenses are fixed; and the risks set forth in Heska's filings and future filings with the Securities and Exchange Commission, including those set forth in Heska's Annual Report on Form 10-K for the year ended December 31, 2004 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2005.
Financial Table Follows (Certain prior year numbers have been reclassified to be consistent with the
current year presentation.): Consolidated Statements of Operations In Thousands, Except per Share Amounts (unaudited) Three Months Ended Twelve Months Ended December 31, December 31, 2004 2005 2004 2005 Revenue, net: Product revenue, net: Core companion animal health $12,803 $13,049 $52,719 $54,716 Other vaccines, pharmaceuticals and products 3,539 2,509 12,968 12,833 Total product revenue, net 16,342 15,558 65,687 67,549 Research, development and other 873 820 2,004 1,888 Total revenue 17,215 16,378 67,691 69,437 Cost of revenue: Cost of products sold 10,450 9,348 42,253 42,515 Cost of research, development and other 388 324 729 1,095 Total cost of revenue 10,838 9,672 42,982 43,610 Gross profit 6,377 6,706 24,709 25,827 Operating expenses: Selling and marketing 3,778 3,309 15,616 14,020 Research and development 1,300 688 5,891 3,749 General and administrative 1,567 1,500 7,442 7,187 Total operating expenses 6,645 5,497 28,949 24,956 Income (loss) from operations (268) 1,209 (4,240) 871 Interest and other expense, net 289 271 575 774 Income (loss) before income taxes (557) 938 (4,815) 97 Income tax expense (benefit) -- (185) -- (185) Net income (loss) $(557) $1,123 $(4,815) $282 Basic and diluted net income (loss) per share $(0.01) $0.02 $(0.10) $0.01 Shares used for basic net income (loss) per share 49,173 49,881 49,029 49,650 Shares used for diluted net income (loss) per share 49,173 51,538 49,029 50,438 Balance Sheet Data In Thousands (unaudited) December 31, December 31, 2004 2005 Cash and cash equivalents $4,982 $5,231 Total current assets 28,442 26,845 Total assets 38,724 36,784 Line of credit 10,375 9,453 Current portion of long-term debt and capital leases 302 1,263 Total current liabilities 23,269 20,722 Long-term debt and capital leases 1,466 2,703 Stockholders' equity 2,579 3,233Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000622/HESKALOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk, firstname.lastname@example.orgHeska Corporation
CONTACT: Jason Napolitano, Executive Vice President & CFO of HeskaCorporation, +1-970-493-7272, ext. 4105
Web site: http://www.heska.com//